Rayoqta

European UnionRefused

Product informationAsk Osler about it

On this page

Indication
Documents
Sources and licences

This page is kept for reference and is not offered to search engines.

Indication

Abicipar Pegol Allergan is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD).

Documents

The official texts, at the regulator.

Summary of product characteristicsEMA
Register entryEMA

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

European Medicines Agency (EMA), European public assessment reports

Source: European Medicines Agency, EPAR list (imported 10 June 2026).

Licence: EMA content, reuse with acknowledgement · Added 10 Jun 2026

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Abicipar pegol
Register: European Union (EMA)
Status: Refused
Status in the register: Application withdrawn
Registration: EMEA/H/C/005103
Marketing authorisation holder: Allergan Pharmaceuticals International Limited
ATC code: S01LA
Group: Sensory organs
Therapeutic area: Macular Degeneration
Procedure: EU centralised
EMA product number: EMEA/H/C/005103